Bioprosthetic tricuspid valve endocarditis caused by Acinetobacter baumannii complex, a case report and brief review of the literature

Journal of Cardiothoracic Surgery

Jia-jun He¹  Zhi-huang Qiu¹  Heng Lu¹  Hua Cao¹  Qiang Chen¹ 

[1] Department of Cardiovascular Surgery, Union Hospital, Fujian Medical University, Xinquan Road 29#, Fuzhou 350001, P. R. China

关键词: Acinetobacter baumannii;    Endocarditis;    Tricuspid valve;   

Others  :  1232270
DOI  :  10.1186/s13019-015-0377-8

 received in 2015-01-10, accepted in 2015-11-02,  发布年份 2015

【 摘 要 】

Background

Species of the genus Acinetobacter are Gram-negative and highly drug-resistant bacilli that normally reside on the skin, oropharynx, and perineum. Several previous studies have reported prosthetic valve endocarditis due to A. baumannii infection.

Case presentation

Here we present a case of late endocarditis of a bioprosthetic tricuspid valve due to A. baumannii complex in a patient who had surgical replacement with a bioprosthetic tricuspid valve six years previously.

Conclusions

We completed tricuspid valve replacement using a 29 mm St. June mechanical prosthetic valve for the patient. Postoperatively, she received intravenous cefoperazone sodium and sulbactam sodium for 2 months and had good recovery.

【 授权许可】

   
2015 Chen et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Roberts WC, Buchbinder NA. Right-sided valvular infective endocarditis. A clinicopathologic study of twelve necropsy patients. Am J Med. 1972; 53:7-19.
• [2]Gottardi R, Bialy J, Devyatko E, Tschernich H, Czerny M, Wolner E, et al. Midterm follow-up of tricuspid valve reconstruction due to active infective endocarditis. Ann Thorac Surg. 2007;84:1943–8.
• [3]Karchmer AW, Dismukes WE, Buckley MJ, Austen WG. Late prosthetic valve endocarditis: clinical features influencing therapy. Am J Med. 1978; 64(2):199-206.
• [4]Pachon J, Vila J. Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Investig Drugs. 2009; 10(2):150-6.
• [5]Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010; 23(4):332-9.
• [6]Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect. 2002; 8(11):687-93.
• [7]Karchmer AV. Infections of prosthetic valves. In: Principles and practice of infectious diseases. 5th ed. Mandell GL, Bennett JE, Dolin R, editors. Churchill Livingstone, Philadelphia; 2000: p.903-17.
• [8]Olut AI, Erkek E. Early prosthetic valve endocarditis due to Acinetobacter baumannii: a case report and brief review of theliterature. Scand J Infect Dis. 2005; 37(11–12):919-21.
• [9]Menon T, Shanmugasundaram S, Nandhakumar B, Nalina K, Balasubramaniam. Infective endocarditis due to Acinetobacter baumannii complex--a case report. Indian J Pathol Microbiol. 2006;49(4):576–8.
• [10]Kumar SS, Vengadassalapathy L, Menon T. Prosthetic valve endocarditis caused by Acinetobacter baumannii complex. Indian J Pathol Microbiol. 2008; 51:573.
• [11]Gradon JD, Chapnick EK, Lutwick LI. Infective endocarditis of a native valve due to Acinetobacter: case report and review. Clin Infect Dis. 1992; 14(5):1145-8.
• [12]Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al. Treatment of endocarditis with valve replacement: The question of tissue versus mechanical prosthesis. Ann Thorac Surg. 2001;71:1164–71.
• [13]Rizzoli G, Vendramin I, Nesseris G et al.. Biological or mechanical prostheses in tricuspid position? A metaanalysis of intra-institutional results. Ann Thorac Surg. 2004; 77:1607-14.
• [14]Carrier M, Hebert Y, Pellerin M et al.. Tricuspid valve replacement: an analysis of 25 years of experience at single center. Ann Thorac Surg. 2003; 75:47-50.
• [15]Gaca JG, Sheng S, Daneshmand M et al.. Current outcomes for tricuspid valve infective endocarditis surgery in North America. Ann Thorac Surg. 2013; 96:1374-81.
• [16]Morimoto N, Matsushima S, Aoki M, Henmi S, Nishioka N, Murakami H, et al. Long-term results of bioprosthetic tricuspid valve replacement: an analysis of 25 years of experience. Gen Thorac Cardiovasc Surg. 2013;61:133–8.